High GAL-3 may be Associated with Higher Age and Low Levels of Chloride, RDW, and MCHC in Heart Failure

Year 2016, Volume: 2 Issue: 4, 159 - 165, 01.10.2016

Aysem Kaya Evin Ademoglu Zerrin Yigit Sevim Purisa İsil Uzunhasan

https://doi.org/10.5455/umj.20161215092108

Abstract

Introduction: Elevated galectin-3 GAL-3 levels has been associated with decompensated heart failure HF which is a complex mechanical and neurohormonal syndrome. Many clinical and biochemical factors have been implicated in the pathophysiology of HF. In a group of patients who are referred to the emergency clinic for HF, GAL-3 levels and their association with various clinical and biochemical parameters were determined. GAL-3levels were measured with the VIDAS® automated enzyme-linked fluorescent assay BioMérieux, France . Method: Our study group consists of 70 patients 33 women and 37 men and 25 healthy controls. All 70 patients had at least Class II or higher levels of HF according to NYHA criteria. Results: GAL-3 was significantly higher in the patient's group 17.98 vs. 10.24 ng/mL; p

Keywords

Galectin-3, Heart Failure, RDW, Hyponatremia, Anemia, MCHC

References

• Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicarefee-for-service program. N Engl J Med. 2009;360:1418-1428.
• Boer RA, vanVeldhuisen DJ, Gansevoort RT, MullerKobold AC, vanGilst WH, Hillege HL, Bakker SJ,van der Harst P.The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012;272(1):55-64.
• Peacock F.How galectin-3 changes acute heart failure decision making in the emergency department. Clin Chem Lab Med. 2014; 52(10): 1409–1412.
• Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Schroen B, Andrè S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure- prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation. 2004; 110(19):3121-3128.
• Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Körfer R, Klein M, Krahn T, Kruska L, El Bnayosy A, Kramer F. J Heart LungTransplant. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory devices. J Heart Lung Transplant. 2008;27(6):589-596.
• Van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino grup-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217-24.
• Jaarsma T, van der Wal MH, Lesman-Leegte I, Luttik ML, Hogenhuis J, Veeger NJ, Sanderman R, Hoes AW, van Gilst WH, Lok DJ, Dunselman PH, Tijssen JG, Hillege HL, van Veldhuisen DJ. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168:316-24.
• Filipe MD, Meijers WC, Rogiervan der Velde A, de Boer RA. Galectin-3 and heart failure: prognosis, prediction & clinical utility.Clin Chim Acta. 2015;443:48-56.
• Zhang Y, Zhang R, An T, Huang Y, Guo X, Yin S, Wang Y, Ji S, Lv R, Zhang J, Maisel A. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure. J Card Fail. 2015;21(1):51-59.
• McCullough P, de Boer RA, Edelmann F, Lewis CM, Maisel AS.Utilization of galectin-3 in case management across the spectrum of heart failure. Rev Cardiovasc Med. 2014;15(3):197-207.
• Zamora E, Lupón J, de Antonio M, Galán A, Domingo M, Urrutia A Troya M, Bayes-Genis A. Renal function largely influences Galectin-3 prognostic value in heart failure.Int J Cardiol. 2014;177(1):171-177.
• http://www.nhlbi.nih.gov/health/health-topics/topics/hf.
• http://www.heart.org/HEARTORG/Conditions/HeartFailure /AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328
• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 128(16):240-327.
• Ho JE,Liu C, Lyass A, Courchesna P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012; 60:1249– 1256.
• Sun RR, Lu L, Liu M, Cao Y, Li XC, Liu H, Wang J, Zhang PY. Biomarkers and heart disease. Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2927-35.
• Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL.Usefulness of plasma galectin-3 levels systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108(3):385-90.
• Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca- Bautista P, Morales-Rull JL, Galisteo-Almeda L, Páez-Rubio MI, Arias-Jiménez JL, Aguayo-CanelaM,Pérez-Calvo JI.Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction.Int J Cardiol. 2013;5;169(3):177-82.
• Bozcali E, Polat V, Aciksari G, Opan S, Bayrak IH, Paker N, Karakaya O. Serum concentrations of galectin-3 in patients with cardiac syndrome X. HellenicJ Cardiol. 2014;55(6):457-461.
• Tseliou E, Terrovitis JV, Kaldara EE, Ntalianis AS, Repasos E, Katsaros L, Margari ZJ, Matsouka C, Toumanidis S, Nanas SN, Nanas JN. Red blood cell distribution width is a significant prognostic marker in advanced heartfailure, independent of hemoglobin levels. Hellenic J Cardiol. 2014;55(6):457-61.
• Huang YL, Hu ZD, Liu SJ, Sun Y, Qin Q, Qin BD, Zhang WW, Zhang JR, Zhong RQ, Deng AM.Prognostic value of red blood cell distribution width for patients with heart failure: a systematic review and meta-analysis of cohort studies.PLoSOne. 2014; 18;9(8):e104861.
• Bichara M, Attmane-Elakeb A, Brown D, Essig M, Karim Z, Muffat-Joly M, Micheli L, Eude-Le Parco I, Cluzeaud F, Peuchmaur M, Bonvalet JP, Poirier F, Farman N. Exploring the role of galectin 3 in kidney function: a genetic approach.Glycobiology. 2006;16(1):36-45.
• Simbaqueba C, Shrestha K, Patarroyo M, Troughton RW, Borowski AG, Klein AL, Tang WH. Prognostic implications of relative hypochromia in ambulatory patients with chronic systolic heart failure.Congest Heart Fail. 2013;19(4):180-5.